Hepatitis C Virus Antiviral Drug Resistance and Salvage Therapy Outcomes Across Australia.

Dao Sen WangAmy PhuKristen McKeeSimone I StrasserSinead SheilsMartin WeltmanSue SellarJoshua S DavisMel YoungAlicia BraundGeoffrey C FarrellAnne BlunnDamian HardingLucy RaltonKate MullerScott A DavisonDavid ShawMarnie WoodKrispin HajkowiczRichard SkolenJane DaviesJaclyn Tate-BakerAdam DoyleRhoda TumaSimon HazeldineWendy LamNatalie EdmistonKrista ZohrabWilliam PrattBelinda WatsonAmany ZekryCarlie StephensPaul J ClarkMelany DayGordon ParkHami KimMark WilsonBruce McGarityNatalie MenziesDarren RussellThao LamPeter BoydJen KokJacob GeorgeMark W Douglas

Published in: Open forum infectious diseases (2024)

In our cohort, the SVR rate for sofosbuvir/velpatasvir/voxilaprevir was higher than with other salvage regimens. The presence of NS5A, NS5B, or NS3 RASs did not appear to negatively influence retreatment outcomes.

Keyphrases

hepatitis c virus
dengue virus
human immunodeficiency virus
zika virus
stem cells
skeletal muscle
aedes aegypti
hiv infected